Nexsen Ltd
Nexsen Limited is an Australia-based nanobiotechnology company.
The business
Nexsen Limited is an Australia-based nanobiotechnology company. The Company is focused on development of proprietary biosensing platforms for rapid, high precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural and biosecurity applications. Its product pipeline includes GBS Rapid Sensor, Chronic kidney disease, and bovine mastitis. Its lead product, the GBS Rapid Sensor, is a diagnostic for the detection of human Group B Streptococcus (GBS) in expectant mothers. The Company is also developing a paper-based chronic kidney disease (CKD) test designed for early detection and routine monitoring across both clinics and at-home use. The bovine mastitis test is designed to test bovine mastitis in cows.
Small Caps Research
No research on Nexsen Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise NXN based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Nexsen Enters into Molecular GBS Diagnostic Joint Venture with FlashDx Shenzhen
Nexsen to form a 50:50 GBS diagnostic JV with FlashDx Shenzhen, targeting FDA 510(k) and EU IVDR clearance and APAC market entry.
Nexsen Secures First Asian Hospital Partner for Diagnostic Commercialisation
Nexsen signs binding term sheet with GHK Hospital to validate and roll out rapid point-of-care diagnostics in North Asia, starting with GBS and kidney tests.
Nexsen Awarded $1.2m Grant to Advance Strepsure Point-Of-Care Diagnostic in Asia-Pacific Markets
Nexsen awarded $1.2m grant to advance StrepSure GBS test in Asia-Pacific; Hong Kong as hub for validation, local manufacturing and near-term commercialization.
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.